Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2003

View Archived Issues

Cardioprotective effects of cariporide in pig model of limited ischemia/reperfusion

Drug pipeline for osteoarthritis

Antiinflammatory effects of montelukast in cystic fibrosis

Rosuvastatin superior to pravastatin or simvastatin in hypercholesterolemia trial

Immunomodulatory effects of WY-14643 demonstrated in mice

Antidepressant-like changes induced by SAMe in the brain of elderly volunteers

Novel glucose- and lipid-lowering agents in early development at Kyoto Pharmaceutical

Fujisawa describes dual adenosine A1/A2A antagonists for depression, dementia, etc.

Janssen presents novel agents for lowering intracranial pressure

New 5-HT6 antagonists with utility in obesity, NIDDM and CNS disorders

Schering presents new inhibitors of CDK and/or GSK-3

Recent Tanabe Seiyaku patent covers novel inhibitors of apo B secretion

Apoptosis-inducing glucose derivatives prepared and tested by Nisshin Seifun and Kyorin team

Medarex and diaDexus form antibody therapeutic collaboration

Tularik reports recent clinical highlights

Safety of ThGRF demonstrated in patients with type 2 diabetes

Replicon NeuroTherapeutics awarded grant for replicon development

Pharmexa reprioritizes programs

Kaleidos's TGF-alpha to be studied for AIDS by NIAID

Encouraging results reported for SomatoKine in adolescent type 1 diabetics

EDEMA1 trial for DX-88 in hereditary angioedema begins patient treatment

Phase II study to evaluate Aptosyn combination regimen in prostate cancer

Study suggests Active Biotech's TASQ drug is suitable for oral dosing

MBI-594AN enters phase IIb for treatment of acne

Complete response letter issued for MedImmune's intranasal flu vaccine

Calpastatin overexpression prevents myocardial injury in rat transplant model

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026